Teva Shares Phase 3 SPACE Trial Results Highlighting The Efficacy And Safety Of AJOVY (Fremanezumab) In Preventing Episodic Migraine In Children And Adolescents

+6.08%

Teva Pharmaceutical Industries Limited Sponsored ADR

TEVA

0.00

AJOVY® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years1
Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed
Full data presented as a late breaker at European Headache Cosgress (EHC) 4-7 December in Rotterdam, Netherlands

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.